What Vyriad does

Vyriad, Inc. is a privately held clinical-stage biopharmaceutical company founded in 2015 (formalized through the March 2016 merger of Omnis Pharma and Magnis Therapeutics) and headquartered in Rochester, Minnesota, where it operates a 12,000 sq. ft. GMP-certified manufacturing facility. The company develops engineered viral vectors spanning lentiviral, vesicular stomatitis virus (VSV), and measles-based platforms, with proprietary G protein engineering and a modular adaptor technology (G-Link) that retargets vectors to specific cell populations including CD3+ T cells. Its portfolio includes a lead clinical oncolytic virotherapy (Voyager-V1, VSV-IFNβ-NIS), a clinical-stage intravesical measles program (MV-NIS), a lead in vivo CAR-T candidate (VV169, BCMA-targeted, first-in-human planned for 2026), and a recently launched research-reagent line (G-Link) distributed through affiliate Imanis Life Sciences.

Vyriad serves large pharmaceutical and biotechnology companies as its primary customer segment through strategic co-development and licensing arrangements — most notably Regeneron Pharmaceuticals (since 2019) and Novartis (since November 2024) — alongside academic medical centers including Mayo Clinic (its co-founding institution) that conduct investigator-sponsored trials. Revenue is generated via upfront payments, development and commercial milestones, and tiered royalties on partnered programs, with secondary income from research-reagent sales and venture/private equity financing (cumulative capital raised exceeds $100M, anchored by an $85M Series B led by Stine Seed Farms).

The company's go-to-market combines enterprise business development targeted at pharma collaborators with strong scientific conference presence (ASH, ASGCT, AACR, ASCO, SITC) and peer-reviewed publication output. Co-founders Stephen Russell, MD/PhD, and Kah-Whye Peng, PhD, both Mayo Clinic scientists, anchor a team of over 90 researchers from 15+ nationalities with cumulative clinical experience dosing over 350 patients across 40+ sites in the USA and Brazil.

Name

Vyriad

Legal name

Vyriad, Inc.

Website

https://vyriad.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Vyriad is a privately held, clinical-stage biopharmaceutical company developing engineered lentiviral, VSV, and measles-based viral vector platforms for in vivo CAR-T, gene therapy, and oncolytic virotherapy, partnering with large pharma (Regeneron, Novartis) and academic centers like Mayo Clinic.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Lentiviral Vector Gene Therapy Developers (HLAAACAB)

akta.pro secondary industries

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)

Keywords

• Oncolytic virotherapy
• Viral vector delivery
• In vivo CAR-T
• Gene therapy platforms
• Cell therapy manufacturing

Headquarters

HQ city

Rochester

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

1. Strategic Collaboration Upfront & Milestone Payments: Preclinical and clinical-stage biotech generates revenue via upfront payments and development/commercial milestones from pharmaceutical partners (e.g., Novartis 2024 deal) for access to its in vivo CAR T lentiviral vector platform.
2. Tiered Royalties on Partnered Programs: Long-term royalty stream on net sales of any partnered products that result from collaborations with pharma companies.
3. Reagent Sales (G-Link Research Products): Sale of proprietary G-Link adaptor protein for research applications via Imanis Life Sciences e-commerce storefront, enabling partner evaluation of the technology.
4. Venture Capital / Private Equity Financing: Privately held clinical-stage biotech funded through venture and private equity investment (e.g., $85M Series B total led by Stine Seed Farms with participation from family offices).

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Vyriad is a clinical-stage biotechnology company that engineers targeted viral delivery platforms for in vivo gene therapy, gene editing, and oncolytic virotherapy. Its core offerings include proprietary lentiviral vector platforms with the G-Link adaptor protein for T-cell targeting, VSV-based and measles-based oncolytic virus platforms, lead clinical assets Voyager-V1 and VV169 (in vivo BCMA CAR-T), and GMP manufacturing services for clinical-grade viral therapeutics.

Product overview

Vyriad is a clinical-stage biotechnology company that offers a platform-plus-modules architecture centered on engineered viral delivery systems for targeted genetic medicines. The portfolio is anchored by two core technology platforms — an Oncolytic Virus Platform comprising the VSV-based Voyager-V1 program and the Measles virus-based MV-NIS program, and an In Vivo Platforms offering that includes the proprietary lentiviral vector delivery system used for in vivo CAR-T and gene editing applications. The modular G-Link adaptor protein technology sits on top of the in vivo platform as a plug-and-play targeting layer that can be applied to both in vivo and ex vivo CAR T workflows, and the lead in vivo CAR-T candidate VV169 (BCMA-targeting multiple myeloma program) is the first clinical translation of this combined platform. Manufacturing is delivered through Vyriad's 12,000 sq. ft. GMP-compliant facility in Rochester, Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

• G-Link: A first-in-class modular adaptor protein technology (trademarked G-Link™) that binds to lentiviral vectors, masks native receptor entry, and retargets delivery to CD3+ T cells, simplifying in vivo and ex vivo CAR T workflows.

Products and services

• G-Link Proteins First-in-class modular adaptor protein that binds to wild-type VSV-G pseudotyped lentiviral vectors, masks native LDLR receptor entry, and retargets delivery to CD3+ T cells. Its trimeric architecture (anti-LDLR domain + anti-CD3 scFv UCHT1) enables high-avidity attachment and plug-and-play use without vector redesign, applicable to both in vivo and ex vivo CAR T workflows and to Cas9-carrying engineered virus-like particles (eVLPs).
• In Vivo Platforms (Targeted Lentiviral Vector Delivery) Vyriad's proprietary lentiviral vector delivery platforms for in vivo CAR-T and gene editing applications. Includes Platform 1 (Blinded, Retargeted VSV-G) which uses a modified VSV-G envelope to deliver transgenes to T cells, and Platform 2 (Trimeric Adapters on G-Link Proteins) which uses plug-and-play adapter caps. Delivers improved transduction efficiency, serum stability, complement resistance, and cell-specific targeting versus first-generation vectors.
• Oncolytic VSV Platform Vesicular stomatitis virus-based oncolytic virus platform administered intravenously for systemic cancer therapy. Vyriad has proprietary technology to rapidly engineer VSV to boost anticancer activity and enable noninvasive monitoring (e.g., via NIS reporter gene). Most patients lack pre-existing antiviral antibodies to VSV, making it applicable across diverse cancer indications.
• Oncolytic Measles Virus Platform (MV-NIS) Measles virus platform encoding the human thyroidal sodium iodide symporter (NIS), administered intratumorally or intravesically. Uses a fusogenic intercellular killing mechanism (formation of non-viable syncytia), with genetically programmable targeting and carrier-cell delivery to circumvent pre-existing anti-measles immunity in many patients.
• Voyager-V1 (VSV-hIFNbeta-NIS) Vyriad's lead clinical-stage VSV-based oncolytic virus, engineered with interferon beta (IFNβ) for enhanced tumor selectivity and the NIS reporter gene for noninvasive SPECT/PET imaging-based tracking. Being developed as monotherapy and in combination with immune checkpoint inhibitors (cemiplimab, pembrolizumab, avelumab). In a Phase 1 T-cell lymphoma trial, more than half of patients responded and a third achieved complete responses lasting 5-30 months.
• VV169 (BCMA-Targeting In Vivo CAR-T) Vyriad's lead in vivo CAR-T candidate designed as a single intravenous administration of a B-cell maturation antigen (BCMA)-targeted CAR transgene, delivered via the LV-169 lentiviral vector. Being developed in partnership with Mayo Clinic for relapsed or treatment-refractory multiple myeloma. Preclinical data showed complete OPM-2 tumor clearance in 100% of humanized mice within 28 days at all dose levels; first-in-human Phase 1 trial planned for 2026.
• MV-NIS (Bladder Cancer Program) Vyriad's measles virus-based clinical program encoding NIS for noninvasive imaging, in Phase 1 testing as intravesical therapy in patients with urothelial carcinoma undergoing radical cystectomy but ineligible for neoadjuvant chemotherapy (NCT03171493).
• GMP Manufacturing Services Vyriad's 12,000 sq. ft. GMP-compliant manufacturing facility in Rochester, Minnesota, with years of experience manufacturing vesicular stomatitis virus (VSV), lentiviral, and measles-based therapies. Has dosed over 200 patients with Vyriad-manufactured drugs in Phase 1 and 2 trials. Supports continuous supply and scalable production from early to late phase clinical trials.

Quantifiable outcome

• 100% of humanized mice with disseminated multiple myeloma achieved complete tumor clearance within 28 days of a single IV dose of VV169 across all tested dose levels (preclinical)
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered minor, core and flagship / core.

• Roger A. Lindahl, CPA (Mayo Clinic)minorOthers · 1 October 2025Senior finance executive and former Chair of Mayo Clinic's Financial Reporting and Consolidations, appointed Chief Financial Officer of Vyriad; not a corporate partnership but a leadership/board connection referencing Mayo Clinic financial leadership pipeline.
• Weizmann Institute of Science (via Yeda Research and Development)coreOEM/ Whitelabel/ Licensing Partner · 2 September 2025Exclusive license agreement signed September 2, 2025 for a novel in vivo gene delivery technology developed at the Weizmann Institute by Professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin. The technology introduces a small, reversible adapter peptide that binds to a targeting protein on engineered viruses, temporarily masking native receptors while presenting a new targeting domain - preserving fusogenic function and potency while enabling high targeting specificity. Vyriad will incorporate the technology into selected development programs within its suite of viral and nanoparticle delivery systems.
• Novartisflagship / coreStrategic or Co-development Partner · 20 November 2024Strategic collaboration announced November 20, 2024 to discover and develop in vivo CAR-T cell therapies. Combines Vyriad's active targeting lentiviral vector platform with Novartis' expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad receives upfront payment, milestone payments, and tiered royalties on each program.
• Regeneron Pharmaceuticalsflagship / coreStrategic or Co-development Partner · 1 November 2019Broad-based strategic research collaboration established in November 2019 to discover and develop new oncolytic virotherapies leveraging Vyriad's VSV platform combined with Regeneron's antibody discovery capabilities. Includes Phase 2 clinical study of Voyager-V1 (Vyriad's lead VSV-based oncolytic virotherapy) in combination with Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) across multiple cancer indications (skin, lung, liver, uterine cancers; NSCLC; melanoma). Vyriad received an upfront payment and equity investment from Regeneron. Vyriad and Regeneron are jointly designing and validating a new generation of precision targeted VSV therapies.
• Merck KGaA and PfizerminorStrategic or Co-development Partner · 28 July 2018Collaboration announced July 28, 2018 to evaluate Vyriad's oncolytic virus Voyager-V1 in combination with avelumab (anti-PD-L1 antibody co-developed by Merck KGaA, Darmstadt, Germany and Pfizer) in a Phase 1 clinical study for metastatic colorectal cancer.
• Tessa TherapeuticsminorStrategic or Co-development Partner · 25 April 2017Partnership announced April 25, 2017 to create next generation of cancer immunotherapy treatments by combining Tessa's Virus Specific T cell (VST) platform with Vyriad's oncolytic viruses, with the goal of effectively targeting a broad range of hard-to-treat solid tumors.
• Imanis Life Sciences (Theranostics Agreement)minorStrategic or Co-development Partner · 16 August 2016Agreement announced August 16, 2016 for development of theranostic tests to predict responsiveness to oncolytic virotherapy. Builds on the broader Vyriad-Imanis research and commercial relationship.
• StingInn, LLCminorOEM/ Whitelabel/ Licensing Partner · 1 January 2016Exclusive license agreement signed for STING technology for development of enhanced oncolytic virotherapy treatments. Vyriad secured an equity position in StingInn, LLC.
• Mayo Clinicflagship / coreStrategic or Co-development PartnerCo-founding institution of Vyriad (co-founders Stephen Russell, MD, PhD and Kah-Whye Peng, PhD are Mayo Clinic scientists). Mayo Clinic is a nonprofit organization committed to clinical practice, education and research. Vyriad and Mayo Clinic have ongoing clinical research agreements to study Voyager-V1 across multiple cancer indications as monotherapy and in combination with other immunotherapies. Co-founders hold joint Mayo Clinic/Vyriad positions.
• Imanis Life SciencescoreImplementation/ SI/ Consulting PartnerVirus engineering contract research organization based in Rochester, Minnesota. Imanis accelerates progress in regenerative medicine, provides clinical assays and research services, and collaborates closely with Vyriad on virus engineering and characterization. Imanis distributes Vyriad's G-Link research reagent (e.g., on imanislife.com/collections/g-link/). Described as an affiliate of Vyriad, Inc.
• Profectus BioSciencesminorStrategic or Co-development PartnerGlobal collaboration to develop oncolytic recombinant VSV (rVSV) vaccines for cancer immunotherapy. Announced in conjunction with Vyriad's formation from Omnis Pharma / Magnis Therapeutics merger.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Replimune Group: Clinical-stage biotechnology company developing proprietary oncolytic virus platforms (RP1, RP2, RP3 based on HSV) for cancer treatment. Direct competitor to Vyriad in the oncolytic virotherapy space, with overlapping clinical development strategy combining oncolytic viruses with checkpoint inhibitors and similar Phase 2 development stage.
• Turnstone Biologics: Clinical-stage company developing oncolytic virus immunotherapies (lead program TIDAL-01) using a vaccinia virus platform for solid tumors. Comparable to Vyriad as an oncolytic virus developer targeting similar cancer indications and pursuing combination strategies with immunotherapy.
• Targovax: Clinical-stage immuno-oncology company developing oncolytic virus platforms (ONCOS-102 and ONCOS-530) for solid tumor treatment. Direct peer to Vyriad's oncolytic virotherapy programs with similar Phase 1/2 development stage and combination immunotherapy approach.
• Tessa Therapeutics: Clinical-stage cell therapy company developing Virus-Specific T cell (VST) therapies for solid tumors. Direct peer and existing collaboration partner of Vyriad - the 2017 agreement combined Tessa's VST platform with Vyriad's oncolytic viruses, making it a comparable peer in the engineered virus/cell therapy space.

Emerging players

• Capsida Biotherapeutics: Gene therapy company developing engineered AAV capsids for targeted in vivo delivery to specific tissues including CNS. Comparable to Vyriad in pursuing targeted in vivo gene delivery, though using AAV rather than lentiviral vectors - emerging player in the broader targeted gene therapy delivery category.
• Umoja Biopharma: Clinical-stage company developing in vivo CAR-T therapies using lentiviral delivery with its VivoVec platform targeting T cells. Most direct emerging competitor to Vyriad's VV169 in vivo CAR-T approach, pursuing similar therapeutic strategy with overlapping target indications.
• Generation Bio: Clinical-stage genetic medicines company developing non-viral LNP delivery systems for gene therapy and gene editing. Comparable to Vyriad in pursuing scalable in vivo genetic medicine delivery, though with non-viral rather than viral vector technology - represents an alternative platform approach to the same opportunity.
• Capstan Therapeutics: Emerging in vivo cell therapy company developing targeted LNP delivery for in vivo CAR-T and gene editing applications. Direct emerging competitor to Vyriad's in vivo CAR-T approach using a different (LNP) delivery modality, with comparable early-stage positioning and similar therapeutic target opportunities.

Broad incumbents

• Intellia Therapeutics: Clinical-stage gene editing company developing in vivo CRISPR/Cas9-based therapies using LNP delivery. Comparable to Vyriad as a broader in vivo genetic medicine platform company with multiple programs in clinical development and larger capitalization, representing the incumbent scale Vyriad aspires to reach.
• Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies using LNP delivery for cardiovascular disease. Comparable to Vyriad as an in vivo genetic medicine company with clinical-stage assets, broader incumbent in the in vivo gene therapy/editing category with multiple programs advancing.

Market position

Strengths5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/VyriadMN
• Facebookfacebook.com/Vyriad
• LinkedInlinkedin.com/company/vyriad
• Instagraminstagram.com/vyriad

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyriad